巴菟补肾益肝颗粒联合聚乙二醇干扰素治疗HBeAg阳性慢性乙型肝炎临床疗效观察

Clinical efficacy observation of Batu Bushen Yigan Granule combined with pegylated interferon in the treatment of HBeAg-positive chronic hepatitis B

目的观察巴菟补肾益肝颗粒联合聚乙二醇干扰素治疗HBeAg阳性慢性乙型肝炎的临床疗效。方法将120例HBeAg阳性慢性乙型肝炎患者随机分为治疗组与对照组,每组60例。治疗组给予巴菟补肾益肝颗粒联合聚乙二醇干扰素治疗,对照组给予中药安慰剂联合聚乙二醇干扰素治疗。疗程均为48周,观察临床疗效,比较肝炎指标及肝功能的变化情况。结果 (1)治疗组、对照组总有效率分别为93.3%、43.3%;两组临床疗效比较,差异有统计意义(P<0.05)。(2)治疗组HBsAg和HBeAg水平的下降幅度明显大于对照组(P<0.05)。(3)治疗组HBV-DNA转阴率明显高于对照组(P<0.05)。(4)治疗组ALT、AST复常率明显优于对照组(P<0.05)。结论巴菟补肾益肝颗粒联合聚乙二醇干扰素治疗慢性乙型肝炎,能够有效降低患者HBsAg和HBeAg的表达,提高HBV-DNA转阴率,改善肝功能。

Objective To observe the clinical efficacy of Batu Bushen Yigan Granule combined with pegylated interferon in the treatment of HBeAg-positive chronic hepatitis B( CHB). Methods 120 CHB patients with HBeAg-positive were randomly divided into the treatment group and control group,60 cases in each group.The treatment group was treated with Batu Bushen Yigan Granule and pegylated interferon,the control group was treated with placebo of Chinese medicine and pegylated interferon. The treatment course of both groups was 48 weeks. The clinical efficacy and the levels of serum HBV-DNA,HBeAg,HBsAg and liver function indexes in both groups were observed before and after treatment. Results(1)The total effective rates were 93.3% in the treatment group and 43.3% in the control group. There was statistically significant difference on the clinical efficacy between the two groups( P<0.05).(2)The decrease of HBsAg and HBeAg levels in the treatment group was obviously greater than those in the control group( P<0.05).(3)The negative conversion rate of HBV-DNA in the treatment group was obviously higher than that in the control group( P<0.05).(4)The recovery rates of ALT and AST in the treatment group were obviously better than those in the control group( P<0.05). Conclusion Batu Bushen Yigan Granule combined with pegylated interferon can effectively reduce HBsAg and HBeAg and increase the negative conversion rate of HBV-DNA and improve the liver function.